DocCheck AG
DocCheck AG offers community, agency, and e-commerce services for the healthcare sector in Europe. The company develops and implements communication strategies for media on healthcare and business-to-business sectors; sells medical supplies and medical technology primarily via mail order to various medical professional groups, and invests in healthcare sectors, as well as involved in online adver… Read more
DocCheck AG (AJ91) - Net Assets
Latest net assets as of June 2025: €38.73 Million EUR
Based on the latest financial reports, DocCheck AG (AJ91) has net assets worth €38.73 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€53.98 Million) and total liabilities (€15.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €38.73 Million |
| % of Total Assets | 71.75% |
| Annual Growth Rate | 4.06% |
| 5-Year Change | 27.83% |
| 10-Year Change | 103.89% |
| Growth Volatility | 10.39 |
DocCheck AG - Net Assets Trend (2005–2024)
This chart illustrates how DocCheck AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DocCheck AG (2005–2024)
The table below shows the annual net assets of DocCheck AG from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €40.08 Million | +5.38% |
| 2023-12-31 | €38.03 Million | -3.50% |
| 2022-12-31 | €39.41 Million | +3.24% |
| 2021-12-31 | €38.18 Million | +21.76% |
| 2020-12-31 | €31.35 Million | +42.17% |
| 2019-12-31 | €22.05 Million | +5.51% |
| 2018-12-31 | €20.90 Million | +1.32% |
| 2017-12-31 | €20.63 Million | +2.30% |
| 2016-12-31 | €20.17 Million | +2.59% |
| 2015-12-31 | €19.66 Million | +5.77% |
| 2014-12-31 | €18.59 Million | +3.33% |
| 2013-12-31 | €17.99 Million | +0.89% |
| 2012-12-31 | €17.83 Million | -0.93% |
| 2011-12-31 | €18.00 Million | -4.64% |
| 2010-12-31 | €18.87 Million | +1.64% |
| 2009-12-31 | €18.57 Million | +2.36% |
| 2008-12-31 | €18.14 Million | -2.68% |
| 2007-12-31 | €18.64 Million | -2.23% |
| 2006-12-31 | €19.06 Million | +1.28% |
| 2005-12-31 | €18.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DocCheck AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 786.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €24.69 Million | 61.60% |
| Common Stock | €5.07 Million | 12.66% |
| Other Comprehensive Income | €-3.21 Million | -8.00% |
| Other Components | €13.52 Million | 33.75% |
| Total Equity | €40.08 Million | 100.00% |
DocCheck AG Competitors by Market Cap
The table below lists competitors of DocCheck AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BRAVE BISON GR.PLC LS-001
F:RT7
|
$18.00 Million |
|
Pardus Girisim Sermayesi Yatirim Ortakligi A.S.
IS:PRDGS
|
$18.00 Million |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
$18.00 Million |
|
Decibel Cannabis Company Inc
OTCQB:DBCCF
|
$18.01 Million |
|
Omnisystem Co.Ltd
KQ:057540
|
$18.00 Million |
|
Xavis Co. Ltd
KQ:254120
|
$17.99 Million |
|
Wp Energy Public Company Limited
BK:WP
|
$17.99 Million |
|
Sonmez Filament Sentetik Iplik ve Elyaf Sanayi AS
IS:SONME
|
$17.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DocCheck AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 37,332,885 to 40,079,341, a change of 2,746,456 (7.4%).
- Net income of 5,283,363 contributed positively to equity growth.
- Dividend payments of 2,536,908 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €5.28 Million | +13.18% |
| Dividends Paid | €2.54 Million | -6.33% |
| Other Changes | €1.00 | +0.0% |
| Total Change | €- | 7.36% |
Book Value vs Market Value Analysis
This analysis compares DocCheck AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.86x to 1.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €3.16 | €12.20 | x |
| 2006-12-31 | €3.23 | €12.20 | x |
| 2007-12-31 | €3.22 | €12.20 | x |
| 2008-12-31 | €3.29 | €12.20 | x |
| 2009-12-31 | €3.40 | €12.20 | x |
| 2010-12-31 | €3.50 | €12.20 | x |
| 2011-12-31 | €3.32 | €12.20 | x |
| 2012-12-31 | €3.49 | €12.20 | x |
| 2013-12-31 | €3.51 | €12.20 | x |
| 2014-12-31 | €3.65 | €12.20 | x |
| 2015-12-31 | €3.87 | €12.20 | x |
| 2016-12-31 | €4.00 | €12.20 | x |
| 2017-12-31 | €4.08 | €12.20 | x |
| 2018-12-31 | €4.15 | €12.20 | x |
| 2019-12-31 | €4.39 | €12.20 | x |
| 2020-12-31 | €6.12 | €12.20 | x |
| 2021-12-31 | €7.37 | €12.20 | x |
| 2022-12-31 | €7.62 | €12.20 | x |
| 2023-12-31 | €7.37 | €12.20 | x |
| 2024-12-31 | €7.90 | €12.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DocCheck AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.18%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.82%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.52x
- Recent ROE (13.18%) is above the historical average (10.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 3.60% | 5.97% | 0.52x | 1.17x | €-1.19 Million |
| 2006 | 5.04% | 6.94% | 0.62x | 1.18x | €-930.47K |
| 2007 | 3.61% | 4.52% | 0.66x | 1.21x | €-1.17 Million |
| 2008 | 3.37% | 3.89% | 0.74x | 1.17x | €-1.18 Million |
| 2009 | 3.36% | 3.74% | 0.76x | 1.18x | €-1.21 Million |
| 2010 | 4.12% | 4.93% | 0.71x | 1.17x | €-1.09 Million |
| 2011 | 7.96% | 7.95% | 0.84x | 1.19x | €-357.81K |
| 2012 | 6.36% | 6.05% | 0.88x | 1.19x | €-633.29K |
| 2013 | 6.22% | 6.11% | 0.84x | 1.21x | €-662.10K |
| 2014 | 9.31% | 8.51% | 0.85x | 1.29x | €-125.45K |
| 2015 | 14.89% | 10.74% | 1.02x | 1.36x | €946.28K |
| 2016 | 13.30% | 10.27% | 1.01x | 1.29x | €661.57K |
| 2017 | 11.76% | 8.59% | 1.04x | 1.32x | €361.09K |
| 2018 | 10.92% | 8.03% | 1.02x | 1.34x | €191.91K |
| 2019 | 14.26% | 9.71% | 0.98x | 1.49x | €937.90K |
| 2020 | 29.77% | 14.58% | 1.34x | 1.52x | €6.11 Million |
| 2021 | 30.56% | 13.27% | 1.43x | 1.61x | €7.67 Million |
| 2022 | 16.31% | 10.33% | 0.96x | 1.64x | €2.43 Million |
| 2023 | 6.08% | 4.25% | 0.95x | 1.50x | €-1.46 Million |
| 2024 | 13.18% | 9.82% | 0.88x | 1.52x | €1.28 Million |
Industry Comparison
This section compares DocCheck AG's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $2,006,123,250
- Average return on equity (ROE) among peers: -13.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DocCheck AG (AJ91) | €38.73 Million | 3.60% | 0.39x | $18.00 Million |
| Schrödinger, Inc. (43Z) | $557.09 Million | -18.02% | 0.36x | $631.00 Million |
| DACHA STRATEGIC (7DC) | $40.24 Million | 0.65% | 0.08x | $81.97 Million |
| ABL Diagnostics Société anonyme (9BK0) | $6.77 Million | 0.80% | 1.20x | $371.65K |
| Zhejiang Taimei Medical Technology Co., Ltd. (A2V) | $1.04 Billion | -33.28% | 0.39x | $47.71 Million |
| ASCOM HLDG NA SF 0,50 (AH2N) | $80.00 Million | 16.88% | 1.43x | $190.62 Million |
| EM Systems Co. Ltd (EMO) | $17.69 Billion | 7.87% | 0.33x | $74.55 Million |
| Tempus AI (F3M) | $-1.38 Billion | 0.00% | 0.00x | $4.75 Billion |
| Pangenomic Health Inc. (LL3) | $2.24 Million | -118.14% | 0.15x | $4.82 Million |
| MeVis Medical Solutions AG (M3V) | $17.83 Million | 17.76% | 0.45x | $12.89 Million |